Empagliflozin/Linagliptin: A Review in Type 2 Diabetes (Q38577303)

4 September 2017

Empagliflozin/Linagliptin: A Review in Type 2 Diabetes (English)

1 reference

empagliflozin/linagliptin

4 September 2017

1 reference

1 reference

type 2 diabetes

9 December 2023

2

Emma D Deeks

1 reference

4 September 2017

Esther S Kim

1

1 reference

4 September 2017

1 September 2015

1 reference

4 September 2017

1 reference

4 September 2017

75

1 reference

4 September 2017

1547-1557

1 reference

4 September 2017

13

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-015-0457-z

4 September 2017

0 references

cites work

Achievement of goals in U.S. diabetes care, 1999-2010.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Pharmacologic treatment of type 2 diabetes: oral medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Empagliflozin: a review of its use in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Linagliptin: an update of its use in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

SGLT2 inhibition--a novel strategy for diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

The role of incretins in glucose homeostasis and diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Pharmacokinetics of linagliptin in subjects with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Fixed-dose combinations for treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Combine and conquer: advantages and disadvantages of fixed-dose combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

AACE/ACE comprehensive diabetes management algorithm 2015.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0457-Z

The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus

21 January 2018

1 reference

12 December 2020

Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects

1 reference

12 December 2020

Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes

1 reference

12 December 2020

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition

1 reference

12 December 2020

SGLT-2 inhibitors and their potential in the treatment of diabetes

1 reference

12 December 2020

Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes?

1 reference

12 December 2020

SGLT2 Inhibitors May Predispose to Ketoacidosis

1 reference

12 December 2020

Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin

1 reference

12 December 2020

10.1007/S40265-015-0457-Z

Identifiers

DOI

1 reference

PubMed ID

26323340

Dimensions Publication ID

4 September 2017

0 references

1 reference

PubMed ID

26323340